{{Şirket bilgi kutusu|name=Alexion İlaç|type=[[PublicÖzel companyŞirket|Özel]]|founded=1992|founder=Leonard Bell|key_people=Leonard Bell <small>([[Chairman]])</small><br>[[Ludwig N. Hantson]] <small>([[Chief Executive Officer|CEO]])</small>|industry=[[Pharmaceutical industryİlaç|Pharmaceuticalİlaç]]|products=[[Eculizumab|Soliris]]|revenue={{nowrap|{{increase}} US$6,069.1 milyon {{small|(2020)}}}}<ref>https://ir.alexion.com/news-releases/news-release-details/alexion-reports-fourth-quarter-and-full-year-2020-results#:~:text=BOSTON%20%2D%2D(BUSINESS%20WIRE)%2D%2D,the%20same%20period%20in%202019.</ref>|net_income={{nowrap|{{increase}} US$443.3 milyon {{small|(2017)}}}}|assets={{nowrap|{{increase}} US$13,583.3 milyon {{small|(2017)}}}}|equity={{nowrap|{{increase}} US$8,893.1 milyon {{small|(2017)}}}}|num_employees={{decrease}} 2,525|location_city=[[Boston, Massachusetts|Boston]], [[Massachusetts]], ABD|website={{URL|www.alexion.com}}|footnotes=<ref>{{cite web|url=https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn10k12312017.htm |title=Alexion Pharmaceuticals 2017 Annual Report Form (10-K) |publisher=[[U.S. Securities and Exchange Commission]] |date=February 8, 2018 |access-date=August 26, 2018}}</ref><ref>{{Cite web|url=http://fortune.com/fortune500/alexion-pharmaceuticals/|title=Alexion Pharmaceuticals|website=Fortune|access-date=2019-02-09}}</ref>}}'''Alexion Pharmaceuticals Inc.''' ABD merkezli bir ilaç şirketidir. Özellikle nadir hastalıklar olan [[Atipik hemolitik üremik sendrom|hemolitik üremik sendrom atipik]] (AHUS) ve [[paroksismal nokturnal hemoglobinüri]] (PNH) tedavisinde kullanılacak ilaçlar üzerine yoğun çalışmaları var <ref name="Forbes">{{Web kaynağı|url=https://www.forbes.com/companies/alexion-pharmaceuticals/|başlık=Alexion Pharmaceuticals on the Forbes World's Most Innovative Companies List|erişimtarihi=28 September 2012|çalışma=forbes.com}}</ref> Şirket ayrıca otoimmün hastalıklarla ilgili bağışıklık sistemi araştırmalarıyla da ilgilenmektedir. Dünya çapında yaklaşık 2.400 kişiyi istihdam etmektedir. <ref name="Everything">{{Haber kaynağı|url=http://www.bizjournals.com/boston/blog/bioflash/2015/05/everything-you-need-to-know-about-the-8-4b.html|başlık=Everything you need to know about the $8.4B acquisition of Synageva|erişimtarihi=May 8, 2015|yazarlar=Don Seiffert|tarih=May 6, 2015|çalışma=Boston Business Journal}}</ref>
Alexion, şirket merkezini 2018'in ortalarında [[Boston|Boston, Massachusetts'e taşıdı.]] <ref>{{Haber kaynağı|url=http://www.courant.com/news/connecticut/hc-alexion-moving-new-haven-boston-20170911-story.html|başlık=Alexion Exits New Haven For Boston, Agrees To Repay Millions In State Aid|erişimtarihi=2017-09-12|yazarlar=Singer|tarih=2017-09-12|çalışma=[[Hartford Courant]]}}</ref>
